Bristol Myers cell therapy among EMA’s CHMP recommendations 

Among its recommendations at its March meeting, EMA’s CHMP backed approval of BMS’s CAR T therapy Breyanzi for second-line treatment of lymphoma, which could grow the drug’s sales and further build the business case for CAR T cells.

Expansion of CAR T therapy Yescarta axicabtagene ciloleucel into the second-line setting for large B cell lymphoma played a role in that product becoming the first CAR T therapy to reach blockbuster sales. Breyanzi lisocabtagene maraleucel from Bristol Myers Squibb Co. (NYSE:BMY) is under review for second-line diffuse large B cell lymphoma; it is already approved for use after two or more lines of systemic therapy. ...